Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 2
2014 5
2015 4
2016 3
2017 5
2018 6
2019 5
2020 9
2021 5
2022 7
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. Among authors: taus a. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
Dynamic Treatment Stratification Using ctDNA.
Vidal J, Taus A, Montagut C. Vidal J, et al. Among authors: taus a. Recent Results Cancer Res. 2020;215:263-273. doi: 10.1007/978-3-030-26439-0_14. Recent Results Cancer Res. 2020. PMID: 31605234 Review.
Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.
Rocha P, Rodrigo M, Moliner L, Menendez S, Masfarré L, Navarro N, Del Rey-Vergara R, Galindo-Campos M, Taus Á, Giner M, Sanchez I, Rodríguez-Fuster A, Aguiló R, Chalela R, Sánchez-Font A, Belda J, Curull V, Pijuan L, Casadevall D, Clavé S, Bellosillo B, Perera-Bel J, Comerma L, Arriola E. Rocha P, et al. Among authors: taus a. Lung Cancer. 2023 Jul;181:107257. doi: 10.1016/j.lungcan.2023.107257. Epub 2023 May 20. Lung Cancer. 2023. PMID: 37263182
Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19).
Mancebo G, Solé-Sedeño JM, Membrive I, Taus A, Castells M, Serrano L, Carreras R, Miralpeix E. Mancebo G, et al. Among authors: taus a. Int J Gynecol Cancer. 2021 Jun;31(6):914-919. doi: 10.1136/ijgc-2020-001942. Epub 2020 Oct 5. Int J Gynecol Cancer. 2021. PMID: 33020205 Review.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Gomez-Roca C, et al. Among authors: taus a. J Immunother Cancer. 2022 May;10(5):e004076. doi: 10.1136/jitc-2021-004076. J Immunother Cancer. 2022. PMID: 35577503 Free PMC article. Clinical Trial.
Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer.
Clavé S, Jackson JB, Salido M, Kames J, Gerding KMR, Verner EL, Kong EF, Weingartner E, Gibert J, Hardy-Werbin M, Rocha P, Riera X, Torres E, Hernandez J, Cerqueira G, Nichol D, Simmons J, Taus Á, Pijuan L, Bellosillo B, Arriola E. Clavé S, et al. Among authors: taus a. Front Oncol. 2023 Oct 20;13:1225646. doi: 10.3389/fonc.2023.1225646. eCollection 2023. Front Oncol. 2023. PMID: 37927472 Free PMC article.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M, Vilà L, Sala González MÁ, Del Barrio Díaz Aldagalán A, Esteban Herrera B, López Castro R, Álvarez Cabellos R, Doménech M, Falagan S, Moreno Vega A, Aguado C, Barba A, Delgado Ureña MT, Isla D, Bellido Hernández L, Fírvida Pérez JL, Juan-Vidal Ó, Massutí B, Mielgo-Rubio X, Ortega AL, Catot S, Dómine M, Escoín-Pérez C, García Navalón F, Gil-Bazo I, Muñoz S, Rodríguez-Abreu D, Villatoro Roldán RM, Alonso-Jáudenes Curbera G, León-Mateos L, Padilla A, Paredes Lario A, Sánchez-Torres JM, Garrido P; Spanish Lung Cancer Group. Gómez Rueda A, et al. Among authors: taus a. Clin Transl Oncol. 2024 Jul;26(7):1779-1789. doi: 10.1007/s12094-024-03404-9. Epub 2024 Mar 21. Clin Transl Oncol. 2024. PMID: 38512450
Angiopoietin-2 is a negative prognostic marker in small cell lung cancer.
Cañadas I, Taus Á, Villanueva X, Arpí O, Pijuan L, Rodríguez Y, Menéndez S, Mojal S, Rojo F, Albanell J, Rovira A, Arriola E. Cañadas I, et al. Among authors: taus a. Lung Cancer. 2015 Nov;90(2):302-6. doi: 10.1016/j.lungcan.2015.09.023. Epub 2015 Sep 26. Lung Cancer. 2015. PMID: 26428740
47 results